Todos os estudos
RecrutamentoExploratório terapêutico (Fase II)Intervencionista

Open, randomized, IInd phase clinical study evaluating the safety and efficacy of rapamycin in the treatment of drug-resistant epilepsy in children with rare and ultra rare diseases of the central nervous system associated with the activation of the mTOR pathway : BraimTOR-NEURO

This research study, called BraimTOR-NEURO, is looking at a medicine called rapamycin (also known as Rapamune) for children who have epilepsy that hasn't responded well to other treatments. Specifically, it's for children with rare brain conditions where a certain body process, called the mTOR pathway, is overactive. The main goals are to find out how safe rapamycin is and if it can reduce the number of seizures by half or more. Researchers will also look at how the medicine affects a child's overall quality of life. This is a Phase II study, meaning we're still in the early stages of testing this treatment.

Em resumo

Status
Recrutamento
Fase
Exploratório terapêutico (Fase II)
Patrocinador
Instytut Pomnik Centrum Zdrowia Dziecka
Meta de inscrição
50
Iniciar
11 Jan 2025

Sobre o que é este estudo?

This study, called BraimTOR-NEURO, is looking into a medication called rapamycin for children with epilepsy that is very difficult to control with standard treatments. This includes children with rare brain conditions like focal cortical dysplasia and LEATS, where a specific process inside the body's cells, known as the mTOR pathway, is more active than it should be. Scientists believe that calming down this mTOR pathway might help reduce seizures.

The main aims of this study are twofold. Firstly, we want to understand how safe rapamycin is for these children. We will be carefully monitoring for any unwanted side effects and how often they occur. Secondly, we want to see if rapamycin is effective in reducing the number of seizures. We are particularly interested in whether at least half of the children in the study experience a 50% or greater reduction in their seizures.

Beyond safety and seizure reduction, the study will also look at other important aspects. This includes how the treatment affects blood tests, if the benefits last for a reasonable period, and whether the medicine helps improve the overall quality of life for the children and their families. This research is important because it could offer a new treatment option for children living with challenging forms of epilepsy.

Pontos principais

  • Tests rapamycin for drug-resistant epilepsy in children.
  • Focuses on rare brain conditions linked to the mTOR pathway.
  • Aims to check safety and reduce seizures by 50% or more.
  • Involves regular monitoring and follow-up.
  • Could offer a new treatment option for specific epilepsies.

Quem pode ser elegível?

This study is open to both boys and girls of any age who have epilepsy that hasn't improved with other medicines. They must also have a rare brain condition linked to a specific body process called the mTOR pathway. This includes conditions like focal cortical dysplasia and LEATS.

However, not everyone with epilepsy will be able to join. Your child's doctor would need to confirm that their specific type of epilepsy is connected to this mTOR pathway and that other treatments haven't worked well for them. This study is specifically looking at children with these particular kinds of difficult-to-treat epilepsy.

Este estudo pode ser adequado para você?

Responda a estas perguntas rápidas para ver se você pode ser elegível. Este é apenas um guia — a decisão final é da equipe de pesquisa.

  1. Does your child have epilepsy that has been difficult to treat with other medicines?
  2. Has a doctor told you that your child has a rare brain condition like focal cortical dysplasia or LEATS?
  3. Is your child's epilepsy thought to be linked to the 'mTOR pathway'?
  4. Are you able to attend regular clinic visits for monitoring?
Responda a todas as perguntas para ver o seu resultado.

O que envolve a participação?

If your child takes part in this study, they would receive the medicine rapamycin, which is given as a 1 mg/mL oral solution (meaning it's a liquid taken by mouth). They would be monitored very closely by the medical team throughout their time in the study. This would involve regular visits to the clinic for check-ups, blood tests, and to record any changes in their seizures or any side effects they might experience. The total duration of the study involves a treatment period and a follow-up period to make sure the researchers have a full picture of the medicine's effects. The exact number of visits and the full length of participation would be explained in detail by the study team.

Riscos e benefícios potenciais

Potential benefits of joining this study include the possibility that rapamycin could help reduce your child's seizures and potentially improve their quality of life, especially if other treatments haven't worked. However, like all medicines, rapamycin can have side effects. Potential risks include experiencing adverse reactions, which will be carefully monitored by the study team. You and your child have the right to withdraw from the study at any time, for any reason, without it affecting your child's future medical care.

Localizações (1)

Algumas localizações dos sites são aproximadas. Estamos melhorando isso — por favor, verifique com a equipe de teste antes de viajar.
  • —
    Não verificado
    Polônia

Perguntas frequentes

What is rapamycin?

Rapamycin is a medicine that's being tested to see if it can help reduce seizures in children with specific types of epilepsy.

What does 'mTOR pathway' mean?

It's a natural process inside our body's cells. In some rare brain conditions, this pathway can be overactive, which might contribute to epilepsy.

What is a 'Phase II' study?

Phase II means it's an early stage of testing where we look more closely at how safe the medicine is and if it has a positive effect, after initial safety tests.

Will my child definitely get the medicine?

Yes, all participants in this study will receive the active medicine rapamycin, as it's not comparing it to a dummy treatment (placebo).

What are 'adverse reactions'?

These are simply any unwanted or unexpected effects that might happen while taking the medicine. They are carefully watched and recorded.

Como saber mais

Sempre consulte seu médico ou especialista antes de decidir participar de um estudo.

Interessado em participar?

Registre seu interesse

Compartilhe seus detalhes e a equipe de pesquisa para "Open, randomized, IInd phase clinical study evaluating the s…" entrará em contato com você se você for elegível. Sempre fale com seu médico antes de concordar em participar.

Discussão

Discussão da comunidade

Desenvolvido pelo nosso fórum em community.patient.info. Por favor, seja respeitoso — isto não é um conselho médico.